Spots Global Cancer Trial Database for rituximab and hyaluronidase human

Every month we try and update this database with for rituximab and hyaluronidase human cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma	NCT04626791	Mantle Cell Lym...	Acalabrutinib Bortezomib Cyclophosphamid... Cytarabine Doxorubicin Hyd... Prednisone Rituximab Rituximab and H...	18 Years - 75 Years	Academic and Community Cancer Research United
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	NCT05455697	Diffuse Large B... Grade 3b Follic... High Grade B-Ce...	Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved...	18 Years -	University of Washington
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy	NCT03719131	Cutaneous Melan... Cutaneous Melan... Stage III Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... Unresectable Me...	Nivolumab Rituximab and H... Ipilimumab	18 Years -	Emory University
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma	NCT05886036	Nodular Lymphoc... Recurrent Nodul... Refractory Nodu...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Fludeoxyglucose... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H...	18 Years -	National Cancer Institute (NCI)
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma	NCT06337318	Classic Follicu... Follicular Lymp...	Biospecimen Col... Computed Tomogr... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H...	18 Years -	National Cancer Institute (NCI)
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	NCT03864419	Burkitt Lymphom... KSHV-associated... Diffuse Large B...	Rituximab and H... Cyclophosphamid... Vincristine Methotrexate Doxorubicin Doxorubicin Hyd... Prednisone Etoposide Rituximab	2 Years -	Fred Hutchinson Cancer Center
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma	NCT05886036	Nodular Lymphoc... Recurrent Nodul... Refractory Nodu...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Fludeoxyglucose... Mosunetuzumab Positron Emissi... Rituximab Rituximab and H...	18 Years -	National Cancer Institute (NCI)
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	NCT05455697	Diffuse Large B... Grade 3b Follic... High Grade B-Ce...	Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved...	18 Years -	University of Washington
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: